Niagen Bioscience, Inc. Operating Income Loss

• Niagen Bioscience, Inc. showed an increase of +110.7% in Operating Income Loss from 2024 to 2025.
• This data is from Niagen Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), Niagen Bioscience, Inc.'s Operating Income Loss has grown by 907.0%.
• Historical annual values: Fiscal year 2025: $16.28 million | Fiscal year 2024: $7.73 million | Fiscal year 2023: -$5.60 million | Fiscal year 2022: -$18.63 million | Fiscal year 2021: -$27.07 million | Fiscal year 2020: -$19.85 million | Fiscal year 2019: -$31.30 million | Fiscal year 2018: -$33.17 million | Fiscal year 2017: -$16.38 million | Fiscal year 2016: -$2.91 million | Fiscal year 2015: -$2.07 million | Fiscal year 2014: -$5.23 million | Fiscal year 2013: -$4.39 million | Fiscal year 2012: -$11.64 million | Fiscal year 2011: -$7.86 million | Fiscal year 2010: -$2.02 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026